Your browser doesn't support javascript.
loading
Oxaliplatin desensitization for ovarian cancer in pregnancy: A case report.
Nicholson, Kaitlin; Jia, Lily; Rowe, Margaret; Esselen, Katharine; Joseph, Naima; Zera, Chloe A; Lax, Timothy; Shea, Meghan.
Affiliation
  • Nicholson K; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
  • Jia L; Harvard Medical School, Boston, MA, United States.
  • Rowe M; Harvard Medical School, Boston, MA, United States.
  • Esselen K; Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, United States.
  • Joseph N; Department of Medicine, Penn Medicine, Philadelphia, PA, United States.
  • Zera CA; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
  • Lax T; Harvard Medical School, Boston, MA, United States.
  • Shea M; Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Boston Medical Center/Boston University, Boston, MA, United States.
Gynecol Oncol Rep ; 52: 101354, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38435348
ABSTRACT
•Incidence of cancer in pregnancy is rising and successful treatment of these patients requires expert multidisciplinary care.•Platinum hypersensitivity reactions in ovarian cancer are commonly treated with desensitization protocols.•To our knowledge, chemotherapy desensitization in pregnant patients has not been previously reported.•Oxaliplatin desensitization during pregnancy may be safe and feasible.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Document type: Article Affiliation country: United States Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Gynecol Oncol Rep Year: 2024 Document type: Article Affiliation country: United States Country of publication: Netherlands